Fulgent Genetics (FLGT) Stock Price, News & Analysis

Company Overview

Fulgent Genetics, Inc. is a technology-driven clinical diagnostics company that provides genetic testing and laboratory services. The company uses next-generation sequencing and other molecular testing technologies to support the diagnosis, risk assessment and management of inherited diseases, cancer and other medical conditions.

Its offerings include hereditary disease testing, oncology testing, reproductive health testing and specialized genetic panels. Fulgent also provides laboratory-developed tests, pharmacogenetic testing and testing solutions for healthcare providers, hospitals, health systems, employers, pharmaceutical companies and public health organizations. The company previously provided large-scale COVID-19 testing services and has since focused on expanding its broader clinical diagnostics and precision medicine capabilities.

Fulgent Genetics was founded in 2011 and is headquartered in Temple City, California. Its services are primarily offered in the United States, with the company working with healthcare and institutional customers across multiple regions. Ming Hsieh, who founded the company, serves as its chairman and chief executive officer.

Key Stats

• Today's Range: $20.82 to $21.79
• 50-Day Range: $17.61 to $22.45
• 52-Week Range: $13.46 to $31.04
• Volume: 253,934 shs
• Average Volume: 329,192 shs
• Market Capitalization: $598.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.50
• Consensus Rating: Hold

Fulgent Genetics Stock Analysis - MarketRank™

Fulgent Genetics scored higher than 59% of companies evaluated by MarketBeat, and ranked 396th out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Fulgent Genetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.

Upside Potential

Fulgent Genetics has a consensus price target of $27.50, representing about 26.5% upside from its current price of $21.74.

Amount of Analyst Coverage

Fulgent Genetics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Fulgent Genetics are expected to grow in the coming year, from ($3.48) to ($2.76) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fulgent Genetics is -7.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fulgent Genetics is -7.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Fulgent Genetics has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.75% of the float of Fulgent Genetics has been sold short.

Short Interest Ratio / Days to Cover

Fulgent Genetics has a short interest ratio ("days to cover") of 7.18.

Change versus previous month

Short interest in Fulgent Genetics has recently decreased by 3.44%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fulgent Genetics does not currently pay a dividend.

Dividend Growth

Fulgent Genetics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.57

News Sentiment

Fulgent Genetics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Fulgent Genetics this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for FLGT on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

5 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Fulgent Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $117,156.00 in company stock.

Percentage Held by Insiders

36.18% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

48.06% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 10/12/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:FLGT
• CIK: 1674930
• Web: www.fulgentgenetics.com
• Phone: (626) 350-0537
• Fax: 626-454-1667
• Employees: 1,315
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Fulgent Genetics: $27.50
• High Price Target: $36.00
• Low Price Target: $19.00
• Potential Upside/Downside: +26.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$60.51 million
• Net Margins: -26.05%
• Pretax Margin: -28.54%
• Return on Equity: -4.93%
• Return on Assets: -4.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.34
• Quick Ratio: 6.34

Sales & Book Value

• Annual Sales: $322.67 million
• Price / Sales: 1.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $35.80 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 27,510,000
• Free Float: 17,560,000
• Market Cap: $598.07 million
• Optionable: Optionable
• Beta: 0.93